- Home
- SEZL vs RNA Comparison
SEZL vs RNA Comparison
Compare SEZL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- RNA
- Stock Information
- Founded
- SEZL 2016
- RNA 2012
- Country
- SEZL United States
- RNA United States
- Employees
- SEZL N/A
- RNA N/A
- Industry
- SEZL Diversified Financial Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- RNA Health Care
- Exchange
- SEZL Nasdaq
- RNA Nasdaq
- Market Cap
- SEZL 3.3B
- RNA 3.4B
- IPO Year
- SEZL N/A
- RNA 2020
- Fundamental
- Price
- SEZL $106.71
- RNA $30.98
- Analyst Decision
- SEZL Strong Buy
- RNA Strong Buy
- Analyst Count
- SEZL 2
- RNA 12
- Target Price
- SEZL $61.42
- RNA $67.92
- AVG Volume (30 Days)
- SEZL 1.4M
- RNA 1.4M
- Earning Date
- SEZL 05-07-2025
- RNA 05-08-2025
- Dividend Yield
- SEZL N/A
- RNA N/A
- EPS Growth
- SEZL 677.39
- RNA N/A
- EPS
- SEZL 2.97
- RNA N/A
- Revenue
- SEZL $329,060,890.00
- RNA $8,927,000.00
- Revenue This Year
- SEZL $33.01
- RNA N/A
- Revenue Next Year
- SEZL $49.84
- RNA $148.12
- P/E Ratio
- SEZL $35.95
- RNA N/A
- Revenue Growth
- SEZL 91.69
- RNA N/A
- 52 Week Low
- SEZL $11.50
- RNA $21.51
- 52 Week High
- SEZL $115.84
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- SEZL 79.89
- RNA 53.85
- Support Level
- SEZL $96.69
- RNA $30.00
- Resistance Level
- SEZL $115.84
- RNA $32.09
- Average True Range (ATR)
- SEZL 6.44
- RNA 1.79
- MACD
- SEZL 0.63
- RNA 0.13
- Stochastic Oscillator
- SEZL 72.07
- RNA 75.00
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.